CLINICAL_TRIALS
trial_result
· 2020-10-06
Clinical Trial Update: Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy [Phase 2]
Summary
A Phase 2 study evaluating pegcetacoplan (APL-2) for geographic atrophy has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Apellis Pharmaceuticals, Inc. | Conditions: Geographic Atrophy | Phase 2 | Status: COMPLETED | Results posted: 2020-10-06